Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03522142 · ClinicalTrials.gov registry record · Phase 1
A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
NCT03522142 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 83 participants.
The verdict
NCT03522142, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of single-agent INCB081776 (Part 1) and INCB081776 in combination with INCMGA00012 (Part 2).
Interventions
- DRUG INCMGA00012
- DRUG INCB081776
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2018-08-27 |
| Est. Completion | 2025-09-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03522142
The ClinicalTrials.gov registry entry for NCT03522142 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which INCMGA00012 is the first listed.
NCT03522142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03522142 about?
NCT03522142 is a clinical study titled "A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies". The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of single-agent INCB081776 (Part 1) and INCB081776 in combination with INCMGA00012 (Part 2).
What is the current status of trial NCT03522142?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2018-08-27. Estimated completion is 2025-09-10.
What interventions are being tested in trial NCT03522142?
The interventions under investigation include: INCMGA00012 (DRUG), INCB081776 (DRUG).
Who is sponsoring clinical trial NCT03522142?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.